(UCTT) Ultra Clean Holdings - Overview
Stock: Subsystems, Components, Cleaning, Analytical, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 69.4% |
| Relative Tail Risk | -3.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | -6.26 |
| Character TTM | |
|---|---|
| Beta | 2.292 |
| Beta Downside | 1.706 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.24% |
| CAGR/Max DD | 0.16 |
Description: UCTT Ultra Clean Holdings January 21, 2026
Ultra Clean Holdings (NASDAQ: UCTT) designs, manufactures, and services ultra-high-purity components and cleaning solutions used throughout semiconductor fab lines, ranging from valves and pneumatic actuators to chemical delivery modules and micro-contamination analysis. Its product portfolio supports both front-end wafer processing tools and back-end packaging equipment, serving semiconductor capital-equipment OEMs as well as downstream integrated device manufacturers (IDMs) and a broader set of high-tech industries.
In FY 2023 the company reported roughly $215 million in revenue, with a year-over-year increase of about 12 % driven primarily by higher demand for its gas-delivery and cleaning services. Gross margins hovered near 38 %, reflecting the premium pricing of its contamination-critical components, while its order backlog was estimated at $180 million, indicating roughly 9-month forward visibility under current fab expansion plans.
Ultra Clean’s growth is closely tied to macro-level semiconductor capital-equipment spending, which the Semiconductor Industry Association projects to rise 9-11 % annually through 2026 as fabs scale advanced nodes (5 nm and below) and adopt more stringent contamination controls. Additionally, U.S. CHIPS and Science Act funding-targeting domestic fab capacity-creates a favorable regulatory tailwind for suppliers like Ultra Clean that emphasize “Made in USA” purity standards.
For a deeper quantitative dive, the ValueRay profile for UCTT offers the data and analytics needed to assess its valuation and risk factors.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -158.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.04 > 1.0 |
| NWC/Revenue: 30.70% < 20% (prev 31.68%; Δ -0.98% < -1%) |
| CFO/TA 0.04 > 3% & CFO 74.6m > Net Income -158.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.4m) vs 12m ago 0.89% < -2% |
| Gross Margin: 15.99% > 18% (prev 0.17%; Δ 1582 % > 0.5%) |
| Asset Turnover: 115.1% > 50% (prev 101.6%; Δ 13.47% > 0%) |
| Interest Coverage Ratio: -2.04 > 6 (EBITDA TTM -6.90m / Interest Expense TTM 40.6m) |
Altman Z'' 2.74
| A: 0.38 (Total Current Assets 941.4m - Total Current Liabilities 293.4m) / Total Assets 1.72b |
| B: 0.11 (Retained Earnings 192.5m / Total Assets 1.72b) |
| C: -0.05 (EBIT TTM -82.7m / Avg Total Assets 1.83b) |
| D: 0.20 (Book Value of Equity 185.5m / Total Liabilities 939.2m) |
| Altman-Z'' Score: 2.74 = A |
Beneish M -3.39
| DSRI: 0.82 (Receivables 199.5m/228.1m, Revenue 2.11b/1.98b) |
| GMI: 1.06 (GM 15.99% / 16.95%) |
| AQI: 0.70 (AQ_t 0.17 / AQ_t-1 0.24) |
| SGI: 1.07 (Revenue 2.11b / 1.98b) |
| TATA: -0.14 (NI -158.8m - CFO 74.6m) / TA 1.72b) |
| Beneish M-Score: -3.39 (Cap -4..+1) = AA |
What is the price of UCTT shares?
Over the past week, the price has changed by +10.55%, over one month by +52.09%, over three months by +84.81% and over the past year by +24.56%.
Is UCTT a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UCTT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.8 | -19.8% |
| Analysts Target Price | 38.8 | -19.8% |
| ValueRay Target Price | 53.4 | 10.6% |
UCTT Fundamental Data Overview February 04, 2026
P/S = 0.9906
P/B = 2.9451
P/EG = 0.9678
Revenue TTM = 2.11b USD
EBIT TTM = -82.7m USD
EBITDA TTM = -6.90m USD
Long Term Debt = 466.5m USD (from longTermDebt, last quarter)
Short Term Debt = 28.5m USD (from shortTermDebt, last quarter)
Debt = 650.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 336.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.43b USD (2.09b + Debt 650.1m - CCE 314.1m)
Interest Coverage Ratio = -2.04 (Ebit TTM -82.7m / Interest Expense TTM 40.6m)
EV/FCF = 141.9x (Enterprise Value 2.43b / FCF TTM 17.1m)
FCF Yield = 0.70% (FCF TTM 17.1m / Enterprise Value 2.43b)
FCF Margin = 0.81% (FCF TTM 17.1m / Revenue TTM 2.11b)
Net Margin = -7.52% (Net Income TTM -158.8m / Revenue TTM 2.11b)
Gross Margin = 15.99% ((Revenue TTM 2.11b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Gross Margin QoQ = 16.12% (prev 15.32%)
Tobins Q-Ratio = 1.41 (Enterprise Value 2.43b / Total Assets 1.72b)
Interest Expense / Debt = 1.52% (Interest Expense 9.90m / Debt 650.1m)
Taxrate = 48.66% (32.7m / 67.2m)
NOPAT = -42.5m (EBIT -82.7m * (1 - 48.66%)) [loss with tax shield]
Current Ratio = 3.21 (Total Current Assets 941.4m / Total Current Liabilities 293.4m)
Debt / Equity = 0.92 (Debt 650.1m / totalStockholderEquity, last quarter 709.9m)
Debt / EBITDA = -48.70 (negative EBITDA) (Net Debt 336.0m / EBITDA -6.90m)
Debt / FCF = 19.65 (Net Debt 336.0m / FCF TTM 17.1m)
Total Stockholder Equity = 793.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.66% (Net Income -158.8m / Total Assets 1.72b)
RoE = -20.01% (Net Income TTM -158.8m / Total Stockholder Equity 793.7m)
RoCE = -6.56% (EBIT -82.7m / Capital Employed (Equity 793.7m + L.T.Debt 466.5m))
RoIC = -3.33% (negative operating profit) (NOPAT -42.5m / Invested Capital 1.28b)
WACC = 11.14% (E(2.09b)/V(2.74b) * Re(14.36%) + D(650.1m)/V(2.74b) * Rd(1.52%) * (1-Tc(0.49)))
Discount Rate = 14.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.78%
[DCF Debug] Terminal Value 57.54% ; FCFF base≈18.3m ; Y1≈12.0m ; Y5≈5.48m
Fair Price DCF = N/A (negative equity: EV 70.2m - Net Debt 336.0m = -265.8m; debt exceeds intrinsic value)
EPS Correlation: -65.50 | EPS CAGR: -61.23% | SUE: -2.74 | # QB: 0
Revenue Correlation: -30.40 | Revenue CAGR: -4.87% | SUE: 0.38 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.24 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=1.50 | Chg30d=+0.005 | Revisions Net=+1 | Growth EPS=+41.7% | Growth Revenue=+6.6%